Study Of Sunitinib With FOLFIRI In Colorectal Cancer

Phase 2 Completed 71 enrolled Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy, safety and pharmacokinetics of sunitinib plus FOLFIRI (irinotecan, 5-FU and l-leucovorin) in the first-line treatment of Japanese mCRC patients

Timeline

Start: 2008-05
Primary completion: 2010-09
Completion: 2010-09

Publications

Tsuji Y, Satoh T, Tsuji A, Muro K, Yoshida M, Nishina T, Nagase M, Komatsu Y, Kato T, Miyata Y, Mizutani N, Hashigaki S, Lechuga MJ, Denda T. First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study. Cancer Sci. 2012 Aug;103(8):1502-7. doi: 10.1111/j.1349-7006.2012.02320.x. Epub 2012 Jun 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sunitinib	Small molecule	37.5 mg	Oral
Background	Irinotecan	Small molecule	180 mg/m2	Intravenous
Background	Levoleucovorin	Unknown	200 mg/m2	Intravenous
Background	fluorouracil	Small molecule	2400 mg/m2	Intravenous

Study Of Sunitinib With FOLFIRI In Colorectal Cancer

Summary

Timeline

Publications

Drugs

Indications